{
    "info": {
        "nct_id": "NCT03113500",
        "official_title": "A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas",
        "inclusion_criteria": "* Documented informed consent of participant and/or legally authorized representative\n* Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment\n\n  * If unavailable, exceptions may be granted with study principal investigator (PI) approval.\n* Eastern Cooperative Oncology Group (ECOG) status =< 2\n* Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma per World Health Organization (WHO) classification, including:\n\n  * Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) with international protein index (IPI) of 2 or higher (must have bulky [defined as mass >= 10 cm] stage II, or stage III-IV disease)\n  * ALK-negative ALCL\n\n    * NOTE: Per amendment dated 05-10-19, ALCL will no longer be eligible except for Canada.\n  * PTCL-not otherwise specified (NOS)\n  * Angioimmunoblastic T-cell lymphoma (AITL)\n  * Adult T-cell lymphoma/leukemia (ATLL)\n  * Enteropathy-associated T-cell lymphoma (EATL)\n  * Hepatosplenic T-cell lymphoma\n* CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by hematopathology review at the participating institution\n* Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan\n* Absolute neutrophil count (ANC) >= 1,000/mm^3\n\n  * Exception: unless documented bone marrow involvement by lymphoma\n* Platelets >= 50,000/mm^3\n\n  * Exception: unless documented bone marrow involvement by lymphoma\n* Total serum bilirubin =< 1.5 x upper limit of normal (ULN) OR if hepatic involvement by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by lymphoma\n* Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN\n* Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN\n* Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula\n* Left ventricular ejection fraction (LVEF) >= 45%\n* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents, radiation\n\n  * Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH) or 1 cycle of CHP-BV; these participants must initiate day 1 cycle 1 of study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV therapy; Patients who received 1 cycle of CHOP-like or 1 cycle of CHP-BV therapy prior to initiating induction with CHEP-BV are allowed to receive only 5 cycles of CHEP-BV instead of 6 cycles, per investigator's discretion\n* History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years.\n\n  * Exceptions: Non-melanoma skin cancer and in situ cervical cancer\n* Symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular event/stroke or myocardial infarction within the past 6 months\n* Central nervous system involvement by lymphoma, including leptomeningeal involvement\n* History of progressive multifocal leukoencephalopathy (PML)\n* Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy\n* Any known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection\n* Baseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndrome\n* Known severe hypersensitivity to any study related agent excipient(s)\n* Females only: pregnant or breastfeeding\n* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If unavailable, exceptions may be granted with study principal investigator (PI) approval.",
            "criterions": [
                {
                    "exact_snippets": "exceptions may be granted with study principal investigator (PI) approval",
                    "criterion": "principal investigator approval",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) status =< 2",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) status =< 2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exception: unless documented bone marrow involvement by lymphoma",
            "criterions": [
                {
                    "exact_snippets": "documented bone marrow involvement by lymphoma",
                    "criterion": "bone marrow involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Enteropathy-associated T-cell lymphoma (EATL)",
            "criterions": [
                {
                    "exact_snippets": "Enteropathy-associated T-cell lymphoma (EATL)",
                    "criterion": "Enteropathy-associated T-cell lymphoma (EATL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adult T-cell lymphoma/leukemia (ATLL)",
            "criterions": [
                {
                    "exact_snippets": "Adult T-cell lymphoma/leukemia (ATLL)",
                    "criterion": "Adult T-cell lymphoma/leukemia (ATLL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* NOTE: Per amendment dated 05-10-19, ALCL will no longer be eligible except for Canada.",
            "criterions": [
                {
                    "exact_snippets": "ALCL will no longer be eligible except for Canada",
                    "criterion": "ALCL diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "country exception",
                            "expected_value": "Canada"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma per World Health Organization (WHO) classification, including:",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed mature peripheral T-cell or natural killer (NK)-cell lymphoma per World Health Organization (WHO) classification",
                    "criterion": "lymphoma type",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "cell lineage",
                            "expected_value": [
                                "mature peripheral T-cell",
                                "natural killer (NK)-cell"
                            ]
                        },
                        {
                            "requirement_type": "classification system",
                            "expected_value": "World Health Organization (WHO)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Documented informed consent of participant and/or legally authorized representative",
            "criterions": [
                {
                    "exact_snippets": "Documented informed consent of participant",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "participant"
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented informed consent of ... legally authorized representative",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "source",
                            "expected_value": "legally authorized representative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease of at least 1.5 cm on computed tomography (CT) or positron emission tomography (PET)-CT scan",
                    "criterion": "measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "imaging_modality",
                            "expected_value": [
                                "computed tomography (CT)",
                                "positron emission tomography (PET)-CT scan"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula",
            "criterions": [
                {
                    "exact_snippets": "Creatinine clearance of >= 60 mL/min per the Cockcroft-Gault formula",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* PTCL-not otherwise specified (NOS)",
            "criterions": [
                {
                    "exact_snippets": "PTCL-not otherwise specified (NOS)",
                    "criterion": "PTCL-not otherwise specified (NOS)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exception: unless documented bone marrow involvement by lymphoma",
            "criterions": [
                {
                    "exact_snippets": "documented bone marrow involvement by lymphoma",
                    "criterion": "bone marrow involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Women of childbearing potential (WOCBP): negative urine or serum pregnancy test; if the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required",
            "criterions": [
                {
                    "exact_snippets": "Women of childbearing potential (WOCBP)",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "negative urine or serum pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatosplenic T-cell lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Hepatosplenic T-cell lymphoma",
                    "criterion": "Hepatosplenic T-cell lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if hepatic involvement by lymphoma: ALT =< 5 x ULN",
                    "criterion": "alanine aminotransferase (ALT) level with hepatic involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total serum bilirubin =< 1.5 x upper limit of normal (ULN) OR if hepatic involvement by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by lymphoma",
            "criterions": [
                {
                    "exact_snippets": "Total serum bilirubin =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "total serum bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if hepatic involvement by lymphoma: =< 3 x ULN for Gilbert's disease or documented hepatic involvement by lymphoma",
                    "criterion": "total serum bilirubin (with hepatic involvement by lymphoma or Gilbert's disease)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "x ULN"
                            }
                        },
                        {
                            "requirement_type": "condition",
                            "expected_value": [
                                "Gilbert's disease",
                                "documented hepatic involvement by lymphoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) with international protein index (IPI) of 2 or higher (must have bulky [defined as mass >= 10 cm] stage II, or stage III-IV disease)",
            "criterions": [
                {
                    "exact_snippets": "Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL)",
                    "criterion": "anaplastic large cell lymphoma (ALCL)",
                    "requirements": [
                        {
                            "requirement_type": "ALK positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "international protein index (IPI) of 2 or higher",
                    "criterion": "international protein index (IPI)",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must have bulky [defined as mass >= 10 cm] stage II, or stage III-IV disease",
                    "criterion": "disease stage and bulk",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "bulky stage II",
                                "stage III",
                                "stage IV"
                            ]
                        },
                        {
                            "requirement_type": "bulky disease mass",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Angioimmunoblastic T-cell lymphoma (AITL)",
            "criterions": [
                {
                    "exact_snippets": "Angioimmunoblastic T-cell lymphoma (AITL)",
                    "criterion": "Angioimmunoblastic T-cell lymphoma (AITL)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) =< 2 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if hepatic involvement by lymphoma: AST =< 5 x ULN",
                    "criterion": "aspartate aminotransferase (AST) level with hepatic involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ALK-negative ALCL",
            "criterions": [
                {
                    "exact_snippets": "ALK-negative ALCL",
                    "criterion": "anaplastic large cell lymphoma (ALCL)",
                    "requirements": [
                        {
                            "requirement_type": "ALK expression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by hematopathology review at the participating institution",
            "criterions": [
                {
                    "exact_snippets": "CD30-positivity (e.g. at least 1%) by immunohistochemistry confirmed by hematopathology review at the participating institution",
                    "criterion": "CD30 expression",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "detection_method",
                            "expected_value": "immunohistochemistry"
                        },
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "hematopathology review at the participating institution"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy; childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)",
            "criterions": [
                {
                    "exact_snippets": "Agreement by WOCBP and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy",
                    "criterion": "contraception or abstinence during and after study",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use effective birth control or abstain from heterosexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "childbearing potential defined as not being surgically sterilized (men and women)",
                    "criterion": "surgical sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "surgically sterilized",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "childbearing potential defined as ... or have not been free from menses for > 1 year (women only)",
                    "criterion": "menstrual status (women only)",
                    "requirements": [
                        {
                            "requirement_type": "free from menses duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 50,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 50,000/mm^3",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Agreement to allow the use of archival tissue from diagnostic tumor biopsies will be retrieved and submitted post-enrollment",
            "criterions": [
                {
                    "exact_snippets": "Agreement to allow the use of archival tissue from diagnostic tumor biopsies",
                    "criterion": "agreement to use archival tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) >= 45%",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) >= 45%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC) >= 1,000/mm^3",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC) >= 1,000/mm^3",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1000,
                                "unit": "mm^3"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Active >= grade 3 viral, bacterial, or fungal infection within 2 weeks prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Active >= grade 3 viral ... infection within 2 weeks prior to day 1 of protocol therapy",
                    "criterion": "viral infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Active >= grade 3 ... bacterial ... infection within 2 weeks prior to day 1 of protocol therapy",
                    "criterion": "bacterial infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Active >= grade 3 ... fungal infection within 2 weeks prior to day 1 of protocol therapy",
                    "criterion": "fungal infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
            "criterions": [
                {
                    "exact_snippets": "may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
                    "criterion": "ability to comply with study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the investigator",
                    "criterion": "investigator's judgment of participant suitability",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": "suitable for compliance"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Baseline peripheral neuropathy >= grade 2 or patients with the demyelinating form of Charcot-Marie-Tooth syndrome",
            "criterions": [
                {
                    "exact_snippets": "Baseline peripheral neuropathy >= grade 2",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "demyelinating form of Charcot-Marie-Tooth syndrome",
                    "criterion": "demyelinating form of Charcot-Marie-Tooth syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Females only: pregnant or breastfeeding",
            "criterions": [
                {
                    "exact_snippets": "Females only",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known severe hypersensitivity to any study related agent excipient(s)",
            "criterions": [
                {
                    "exact_snippets": "Known severe hypersensitivity to any study related agent excipient(s)",
                    "criterion": "severe hypersensitivity to study related agent excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any known human immunodeficiency virus (HIV) infection, hepatitis B surface antigen-positive status, or known or suspected active hepatitis C infection",
            "criterions": [
                {
                    "exact_snippets": "Any known human immunodeficiency virus (HIV) infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B surface antigen-positive status",
                    "criterion": "hepatitis B surface antigen status",
                    "requirements": [
                        {
                            "requirement_type": "antigen status",
                            "expected_value": "positive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known or suspected active hepatitis C infection",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias), cerebrovascular event/stroke or myocardial infarction within the past 6 months",
            "criterions": [
                {
                    "exact_snippets": "Symptomatic cardiac disease (including symptomatic ventricular dysfunction, symptomatic coronary artery disease, and symptomatic arrhythmias)",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic ventricular dysfunction",
                    "criterion": "ventricular dysfunction",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic arrhythmias",
                    "criterion": "arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "symptom presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "cerebrovascular event/stroke ... within the past 6 months",
                    "criterion": "cerebrovascular event or stroke",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction within the past 6 months",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central nervous system involvement by lymphoma, including leptomeningeal involvement",
            "criterions": [
                {
                    "exact_snippets": "Central nervous system involvement by lymphoma",
                    "criterion": "central nervous system involvement by lymphoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal involvement",
                    "criterion": "leptomeningeal involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exceptions: Non-melanoma skin cancer and in situ cervical cancer",
            "criterions": [
                {
                    "exact_snippets": "Non-melanoma skin cancer",
                    "criterion": "non-melanoma skin cancer",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in situ cervical cancer",
                    "criterion": "in situ cervical cancer",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 years.",
            "criterions": [
                {
                    "exact_snippets": "History of another primary invasive cancer ... that has not been in remission for at least 3 years",
                    "criterion": "history of another primary invasive cancer",
                    "requirements": [
                        {
                            "requirement_type": "remission duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... hematologic malignancy ... that has not been in remission for at least 3 years",
                    "criterion": "history of hematologic malignancy",
                    "requirements": [
                        {
                            "requirement_type": "remission duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... myelodysplastic syndrome that has not been in remission for at least 3 years",
                    "criterion": "history of myelodysplastic syndrome",
                    "requirements": [
                        {
                            "requirement_type": "remission duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of progressive multifocal leukoencephalopathy (PML)",
            "criterions": [
                {
                    "exact_snippets": "History of progressive multifocal leukoencephalopathy (PML)",
                    "criterion": "progressive multifocal leukoencephalopathy (PML)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment of PTCL with systemic anti-lymphoma therapies, investigational agents, radiation",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment of PTCL with systemic anti-lymphoma therapies",
                    "criterion": "prior treatment of PTCL with systemic anti-lymphoma therapies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment of PTCL with ... investigational agents",
                    "criterion": "prior treatment of PTCL with investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment of PTCL with ... radiation",
                    "criterion": "prior treatment of PTCL with radiation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Exception: May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH) or 1 cycle of CHP-BV; these participants must initiate day 1 cycle 1 of study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV therapy; Patients who received 1 cycle of CHOP-like or 1 cycle of CHP-BV therapy prior to initiating induction with CHEP-BV are allowed to receive only 5 cycles of CHEP-BV instead of 6 cycles, per investigator's discretion",
            "criterions": [
                {
                    "exact_snippets": "May have received 1 cycle of CHOP-like therapy (e.g. CHOP, CHOEP, EPOCH) or 1 cycle of CHP-BV",
                    "criterion": "prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "regimen",
                            "expected_value": [
                                "CHOP-like (CHOP, CHOEP, EPOCH)",
                                "CHP-BV"
                            ]
                        },
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "cycle"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "must initiate day 1 cycle 1 of study therapy (CHEP-BV) no less than 19 days from prior CHOP-like or CHP-BV therapy",
                    "criterion": "interval between prior therapy and study therapy initiation",
                    "requirements": [
                        {
                            "requirement_type": "minimum interval",
                            "expected_value": {
                                "operator": ">=",
                                "value": 19,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients who received 1 cycle of CHOP-like or 1 cycle of CHP-BV therapy prior to initiating induction with CHEP-BV are allowed to receive only 5 cycles of CHEP-BV instead of 6 cycles, per investigator's discretion",
                    "criterion": "number of CHEP-BV cycles allowed",
                    "requirements": [
                        {
                            "requirement_type": "maximum cycles",
                            "expected_value": {
                                "operator": "=",
                                "value": 5,
                                "unit": "cycles"
                            }
                        },
                        {
                            "requirement_type": "investigator discretion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study",
            "criterions": [
                {
                    "exact_snippets": "Any other condition that would, in the investigator's judgement, contraindicate the patient's participation in the clinical study",
                    "criterion": "other condition contraindicating participation",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}